Confusing Blood Group Antibodies in Obstetrics: Focus on the Risk of Hemolytic Disease of the Fetus and Newborn

Abstract

During routine prenatal antibody screening, maternal reactivity is sometimes detected for which the clinical significance is unclear. As a result, the strategy for monitoring these antibodies during pregnancy, to mitigate the risk of hemolytic disease of the fetus and newborn (HDFN), may be uncertain. This review focuses on four such immune responses in obstetrics: anti-G, anti-M, warm reactive autoantibodies, and apparent nonspecific immune responses that cannot be further classified. The relationship of these antibodies to HDFN is a primary focus. Related concerns, including maternal and neonatal transfusion considerations and candidacy for Rh immune globulin, are also addressed.

Key Points

• Pregnant patients with anti-G who lack anti-D are candidates for Rh immune globulin.

• Anti-M is a rare cause of HDFN.

• Warm reactive autoantibodies in pregnancy are unlikely to be clinically significant.

Keywords

alloimmunization - anti-G - anti-M - blood group antibodies - hemolytic disease of the fetus and newborn - pregnancy - warm reactive autoantibodies

Publikationsverlauf

Eingereicht: 07. Februar 2025

Angenommen: 26. Mai 2025

Accepted Manuscript online:
27. Mai 2025

Artikel online veröffentlicht:
16. Juni 2025

• References

• 1 Er LS, Bailey DJ. Identification of antibodies to red cell antigens. In: Cohn CS, Delaney M, Johnson ST, Katz LM. eds. AABB Technical Manual. 20th ed. Bethesda, MD: AABB; 2020: 389-428
• 2 Rahimi-Levene N, Chezar J, Yahalom V. Israeli HDFN Study Group Investigators. Red blood cell alloimmunization prevalence and hemolytic disease of the fetus and newborn in Israel: a retrospective study. Transfusion 2020; 60 (11) 2684-2690
• 3 Smith HM, Shirey RS, Thoman SK, Jackson JB. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology 2013; 29 (04) 127-130
• 4 Christensen RD, Bahr TM, Ilstrup SJ, Dizon-Townson DS. Alloimmune hemolytic disease of the fetus and newborn: genetics, structure, and function of the commonly involved erythrocyte antigens. J Perinatol 2023; 43 (12) 1459-1467
• 5 Blackall DP, Tomlinson MW. Alloimmunization to low and high prevalence blood group antigens: rare causes of hemolytic disease of the fetus and newborn. J Perinatol 2024; 45 (02) 287-290
• 6 Peyrard T, Wagner FF. The Rh system. In: Cohn CS, Delaney M, Johnson ST, Katz LM. eds. AABB Technical Manual. 20th ed. Bethesda, MD: AABB; 2020: 329-354
• 7 Evers D, Middelburg RA, de Haas M. et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematol 2016; 3 (06) e284-e292
• 8 Selleng K, Jenichen G, Denker K, Selleng S, Müllejans B, Greinacher A. Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates: a prospective, single-centre, observational study. Lancet Haematol 2017; 4 (05) e218-e224
• 9 Ross MB, de Alarcón P. Hemolytic disease of the fetus and newborn. Neoreviews 2013; 14: e83-e88
• 10 Liu S, Ajne G, Wikman A, Lindqvist C, Reilly M, Tiblad E. Management and clinical consequences of red blood cell antibodies in pregnancy: a population-based cohort study. Acta Obstet Gynecol Scand 2021; 100 (12) 2216-2225
• 11 Visser GHA, Thommesen T, Di Renzo GC, Nassar AH, Spitalnik SL. FIGO Committee for Safe Motherhood, Newborn Health. FIGO/ICM guidelines for preventing Rhesus disease: a call to action. Int J Gynaecol Obstet 2021; 152 (02) 144-147
• 12 Das S, Shastry S, Murugesan M, B PB, Shastry S. What is it really? Anti-G or anti-D plus anti-C: clinical significance in antenatal mothers. Indian J Hematol Blood Transfus 2017; 33 (02) 259-263
• 13 van 't Oever RM, Zwiers C, de Winter D. et al. Identification and management of fetal anemia due to hemolytic disease. Expert Rev Hematol 2022; 15 (11) 987-998
• 14 Savoia HF, Parakh A, Kane SC. How I manage pregnant patients who are alloimmunized to RBC antigens. Blood 2024; 2024: 14
• 15 Melland C, Nance S. Other blood group systems and antigens. In: Cohn CS, Delaney M, Johnson ST, Katz LM. eds. AABB Technical Manual. 20th ed. Bethesda, MD: AABB; 2020: 355-388
• 16 Bryk AH, Wiśniewski JR. Quantitative analysis of human red blood cell proteome. J Proteome Res 2017; 16 (08) 2752-2761
• 17 Aoki T. A comprehensive review of our current understanding of red blood cell (RBC) glycoproteins. Membranes (Basel) 2017; 7 (04) 56
• 18 Thornton NM, Grimsley SP. Clinical significance of antibodies to antigens in the ABO, MNS, P1PK, Rh, Lutheran, Kell, Lewis, Duffy, Kidd, Diego, Yt, and Xg blood group systems. Immunohematology 2019; 35 (03) 95-101
• 19 He Y, Gao W, Li Y, Xu C, Wang Q. A single-center, retrospective analysis of 17 cases of hemolytic disease of the fetus and newborn caused by anti-M antibodies. Transfusion 2023; 63 (03) 494-506
• 20 Golshahi F, Sharbaf FR, Shirazi M. et al. Severe fetal hemolytic disease due to anti-M alloimmunization: a case report and literature review. Case Rep Womens Health 2024; 42: e00620
• 21 Bahr TM, Tweddell SM, Zalla JM. et al. Neonatal and obstetrical outcomes of pregnancies complicated by alloimmunization. Pediatrics 2024; 153 (06) e2023064604
• 22 De Young-Owens A, Kennedy M, Rose RL, Boyle J, O'Shaughnessy R. Anti-M isoimmunization: management and outcome at the Ohio State University from 1969 to 1995. Obstet Gynecol 1997; 90 (06) 962-966
• 23 Stetson B, Scrape S, Markham KB. Anti-M alloimmunization: management and outcome at a single institution. AJP Rep 2017; 7 (04) e205-e210
• 24 Johnson ST, Judd WJ, Storry J. Judd's methods in immunohematology. 4th ed. Bethesda, MD: AABB Press; 2022: 647-650
• 25 Singh B, Chaudhary R, Katharia R. Reassessment of critical anti-D antibody titer in RhD alloimmunized antenatal women. Lab Med 2023; 54 (04) 429-433
• 26 Johnson ST, Judd WJ, Storry J. Judd's methods in immunohematology. 4th ed. Bethesda, MD: AABB Press; 2022: 503-506
• 27 Ohto H, Denomme GA, Ito S, Ishida A, Nollet KE, Yasuda H. Three non-classical mechanisms for anemic disease of the fetus and newborn, based on maternal anti-Kell, anti-Ge3, anti-M, and anti-Jr^a cases. Transfus Apher Sci 2020; 59 (05) 102949
• 28 Ishida A, Ohto H, Yasuda H. et al. Anti-M antibody induced prolonged anemia following hemolytic disease of the newborn due to erythropoietic suppression in 2 siblings. J Pediatr Hematol Oncol 2015; 37 (06) e375-e377
• 29 Li S, He Z, Mo C. et al. Hyporegenerative anemia in anti-M-associated hemolytic disease of the fetus. Transfusion 2021; 61 (06) 1908-1915
• 30 Petz LD, Garratty G. The serologic investigation of autoimmune hemolytic anemia. In: Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004: 201-230
• 31 Blackall DP. Warm-reactive autoantibodies in pediatric patients: clinical and serologic correlations. J Pediatr Hematol Oncol 2007; 29 (11) 792-796
• 32 Wheeler CA, Calhoun L, Blackall DP. Warm reactive autoantibodies: clinical and serologic correlations. Am J Clin Pathol 2004; 122 (05) 680-685
• 33 Borge PD, Mansfield PM. The positive direct antiglobulin test and immune-mediated hemolysis. In: Cohn CS, Delaney M, Johnson ST, Katz LM. eds. AABB Technical Manual. 20th ed. Bethesda, MD: AABB; 2020: 429-456
• 34 Blackall DP, Little JT. Warm reactive autoantibodies detected by solid phase technology: patient characteristics, laboratory features, and clinical significance. Am J Clin Pathol 2024; 162 (03) 282-288
• 35 Yamada C, Serrano-Rahman L, Vasovic LV, Mohandas K, Uehlinger J. Antibody identification using both automated solid-phase red cell adherence assay and a tube polyethylene glycol antiglobulin method. Transfusion 2008; 48 (08) 1693-1698
• 36 Miller NM, Johnson ST, Carpenter E, Naczek CA, Karafin MS. Patient factors associated with unidentified reactivity in solid-phase and polyethylene glycol antibody detection methods. Transfusion 2017; 57 (05) 1288-1293
• 37 Hoppe B, Stibbe W, Bielefeld A, Pruss A, Salama A. Increased RBC autoantibody production in pregnancy. Transfusion 2001; 41 (12) 1559-1561
• 38 Sürücü G, Mayer B, Märzacker A, Yürek S, Salama A. Harmless pregnancy-induced warm autoantibodies to red blood cells. Transfus Med Hemother 2015; 42 (05) 325-327
• 39 Balola AHA, Mayer B, Bartolmäs T, Salama A. A fluorometric erythrophagocytosis assay using differentiated monocytic THP-1 cells to assess the clinical significance of antibodies to red blood cells. Vox Sang 2021; 116 (10) 1106-1116
• 40 Petz LD, Garratty G. Unusual aspects of acquired immune hemolytic anemias, Section D. Autoimmune hemolytic anemia during pregnancy. In: Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004: 345-347
• 41 Blackall DP, Wheeler CA. Contemporaneous autoantibodies and alloantibodies. Transfusion 2007; 47 (07) 1332
• 42 Carter JE, Gallego M, Stubbs JR. The identification of red cell antibodies: a comparative study of a solid phase red cell adherence system, a gel system, and agglutination testing. Am J Clin Pathol 1997; 107: 486-487
• 43 Casina TS. In search of the Holy Grail: comparison of antibody screening methods. Immunohematology 2006; 22 (04) 196-202
• 44 Van Winden KR, Poisson JL, Lee RH, Agarwal R, Ouzounian JG, Shulman IA. Non-specific red cell reactivity in an obstetric population. J Matern Fetal Neonatal Med 2016; 29 (17) 2848-2851
• 45 Liu C, Grossman BJ. Antibody of undetermined specificity: frequency, laboratory features, and natural history. Transfusion 2013; 53 (05) 931-938
• 46 Blackall D, Brech H. Investigation of apparent solid phase-only red cell serologic reactivity: clinical and laboratory correlations. Clin Lab 2023; 69 (07) 1399-1406
• 47 Lu W, Ziman A, Yan MTS. et al. Serologic reactivity of unidentified specificity in antenatal testing and hemolytic disease of the fetus and newborn: the BEST collaborative study. Transfusion 2023; 63 (04) 817-825